Skye Bioscience
SKYE
73 hedge funds and large institutions have $71.3M invested in Skye Bioscience in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 14 closing their positions.
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
1% less funds holding
Funds holding: 74 → 73 (-1)
1.72% less ownership
Funds ownership: 84.81% → 83.09% (-1.7%)
29% less capital invested
Capital invested by funds: $101M → $71.3M (-$29.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$3.45M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.94M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$140K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$134K |
| 5 |
BlackRock
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.63M |
| 2 |
AIC
AWM Investment Company
New York
|
-$1.56M |
| 3 |
Millennium Management
New York
|
-$1.54M |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$825K |
| 5 |
ACM
Altium Capital Management
New York
|
-$736K |
SKYE Hedge Fund Activity: Q4 2024 in Review
73 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q4 2024, worth a combined $71.3M — down 29% from $101M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SKYE and 13 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 29 added.
The largest buyer was Braidwell, opening a new position worth an estimated $3.45M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.63M sold.
- 73 institutional investors held Skye Bioscience (SKYE) as of Q4 2024, down from 74 in Q3 2024.
- Funds reported $71.3M of Skye Bioscience stock for Q4 2024, down 29% quarter-over-quarter.
- 13 funds opened new Skye Bioscience positions in Q4 2024 and 14 closed out, a net change of -1 holder.
- The largest Skye Bioscience buyer in Q4 2024 was Braidwell, an estimated $3.45M added.
- The largest Skye Bioscience seller in Q4 2024 was Point72 Asset Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2024.